Credit Suisse’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Hold |
0
| – | – | – | 4281 |
|
|
2022
Q2 | – | Sell |
-2,022
| Closed | -$193K | – | 4305 |
|
|
2022
Q1 | $198K | Buy |
2,022
+72
| +4% | +$9.24K | ﹤0.01% | 3374 |
|
|
2021
Q4 | $319K | Buy |
1,950
+1,032
| +112% | +$227K | ﹤0.01% | 4096 |
|
|
2021
Q3 | $250K | Buy |
918
+48
| +6% | +$14.7K | ﹤0.01% | 4149 |
|
|
2021
Q2 | $345K | Sell |
870
-193
| -18% | -$90.1K | ﹤0.01% | 4045 |
|
|
2021
Q1 | $574K | Sell |
1,063
-1,032
| -49% | -$642K | ﹤0.01% | 3683 |
|
|
2020
Q4 | $791K | Sell |
2,095
-79
| -4% | -$31.4K | ﹤0.01% | 3503 |
|
|
2020
Q3 | $822K | Buy |
2,174
+119
| +6% | +$52.6K | ﹤0.01% | 3072 |
|
|
2020
Q2 | $1.01M | Buy |
2,055
+541
| +36% | +$241K | ﹤0.01% | 2900 |
|
|
2020
Q1 | $556K | Buy |
1,514
+160
| +12% | +$82.8K | ﹤0.01% | 3048 |
|
|
2019
Q4 | $957K | Buy |
1,354
+3
| +0.2% | +$2.06K | ﹤0.01% | 3161 |
|
|
2019
Q3 | $867K | Buy |
1,351
+675
| +100% | +$535K | ﹤0.01% | 3105 |
|
|
2019
Q2 | $591K | Buy |
676
+75
| +12% | +$51.6K | ﹤0.01% | 3299 |
|
|
2019
Q1 | $346K | Buy |
601
+15
| +3% | +$6.27K | ﹤0.01% | 3538 |
|
|
2018
Q4 | $164K | Buy |
586
+92
| +19% | +$36.4K | ﹤0.01% | 3705 |
|
|
2018
Q3 | $237K | Sell |
494
-251
| -34% | -$108K | ﹤0.01% | 3610 |
|
|
2018
Q2 | $338K | Sell |
745
-152
| -17% | -$96.4K | ﹤0.01% | 3584 |
|
|
2018
Q1 | $527K | Buy |
897
+202
| +29% | +$126K | ﹤0.01% | 3334 |
|
|
2017
Q4 | $432K | Sell |
695
-403
| -37% | -$290K | ﹤0.01% | 3500 |
|
|
2017
Q3 | $1.01M | Buy |
1,098
+289
| +36% | +$257K | ﹤0.01% | 3087 |
|
|
2017
Q2 | $755K | Sell |
809
-409
| -34% | -$401K | ﹤0.01% | 2873 |
|
|
2017
Q1 | $1.16M | Buy |
1,218
+264
| +28% | +$246K | ﹤0.01% | 2756 |
|
|
2016
Q4 | $766K | Buy |
954
+252
| +36% | +$227K | ﹤0.01% | 3217 |
|
|
2016
Q3 | $593K | Sell |
702
-56
| -7% | -$45K | ﹤0.01% | 3328 |
|
|
2016
Q2 | $624K | Sell |
758
-574
| -43% | -$625K | ﹤0.01% | 3283 |
|
|
2016
Q1 | $1.48M | Buy |
1,332
+257
| +24% | +$263K | ﹤0.01% | 2423 |
|
|
2015
Q4 | $1.34M | Sell |
1,075
-1,877
| -64% | -$3.1M | ﹤0.01% | 2584 |
|
|
2015
Q3 | $3.99M | Buy |
2,952
+1,491
| +102% | +$2.46M | ﹤0.01% | 1723 |
|
|
2015
Q2 | $2.63M | Buy |
1,461
+1,001
| +218% | +$1.55M | ﹤0.01% | 2320 |
|
|
2015
Q1 | $743K | Buy |
460
+231
| +101% | +$342K | ﹤0.01% | 3230 |
|
|
2014
Q4 | $175K | Sell |
229
-256
| -53% | -$136K | ﹤0.01% | 4316 |
|
|
2014
Q3 | $191K | Sell |
485
-105
| -18% | -$50.6K | ﹤0.01% | 4149 |
|
|
2014
Q2 | $358K | Sell |
590
-219
| -27% | -$122K | ﹤0.01% | 4010 |
|
|
2014
Q1 | $555K | Buy |
809
+260
| +47% | +$174K | ﹤0.01% | 3631 |
|
|
2013
Q4 | $358K | Buy |
549
+327
| +147% | +$195K | ﹤0.01% | 3964 |
|
|
2013
Q3 | $131K | Sell |
222
-100
| -31% | -$45.1K | ﹤0.01% | 4069 |
|
|
2013
Q2 | $102K | Buy |
+322
| New | +$89.4K | ﹤0.01% | 4011 |
|
Other funds holding TCRT
MP
DCM
LCM
BC
Credit Suisse's TCRT Position: Q3 2022 in Review
Credit Suisse held its Alaunos Therapeutics (TCRT) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4281.
Credit Suisse first reported a position in TCRT in Q2 2013 and has held it in 36 quarters since. The position peaked at $3.99M in Q3 2015. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.
- Credit Suisse held 0 shares of Alaunos Therapeutics worth $0 as of Q3 2022.
- Credit Suisse left its Alaunos Therapeutics share count unchanged in Q3 2022.
- Alaunos Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4281 holding.
- Credit Suisse first reported a position in Alaunos Therapeutics in Q2 2013 and has held it in 36 quarters since.
- Credit Suisse's Alaunos Therapeutics position peaked at $3.99M in Q3 2015.
- 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.
Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.